Agilent “Dialogues in CDx” Podcast Series
Agilent “Dialogues in CDx” Podcast Series
Podcast Description
Tune into candid conversations among professionals in companion diagnostics, an important field in the world of precision medicine. Blending expertise with real-world experience across multiple disciplines, this series aims to illuminate the challenges, approaches, and latest perspectives in companion diagnostics through thoughtful and educational dialogue.
Podcast Insights
Content Themes
The podcast focuses on companion diagnostics in precision medicine, with specific episodes addressing topics such as the complexity of PD-L1 scoring algorithms, the PD-L1 testing journey, and collaborative approaches between pathologists and oncologists. Examples include discussions on diagnostic cutoffs and the importance of efficient testing workflows.
Tune into candid conversations among professionals in companion diagnostics, an important field in the world of precision medicine. Blending expertise with real-world experience across multiple disciplines, this series aims to illuminate the challenges, approaches, and latest perspectives in companion diagnostics through thoughtful and educational dialogue.
Episode 10 of the “Dialogues in CDx” podcast series focuses on the practical aspects of biomarker testing in ovarian cancer and its growing role in treatment decision-making. The discussion explores testing workflows, reflex versus on-demand testing, tissue selection, re-biopsy considerations, and assay validation. The speakers highlight the importance of collaboration between oncologists and pathologists, discuss current challenges in biomarker interpretation, and look ahead to emerging biomarkers and future innovations in precision oncology.
Dr. Brooke Howitt is a gynecologic and sarcoma pathologist at Stanford University whose clinical and research interests focus on gynecologic neoplasms, including the molecular alterations that influence diagnosis, classification, andbiomarker-driven patient care.
Our second guest, Dr. Bradley Monk, is a board-certified gynecologic oncologist with Florida Cancer Specialists & Research Institute. He has led and contributed to numerous practice-changing clinical trials in gynecologic cancers and iswidely recognized for his work advancing precision medicine and novel therapies for women with gynecologic malignancies.
This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay.
For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's CDx Digital Education Portaltoday.
D0151977_1.00
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.